{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:51:27Z","timestamp":1787503887647,"version":"build-2736575974"},"reference-count":109,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0083","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:54:01Z","timestamp":1752836041000},"source":"Crossref","is-referenced-by-count":1,"title":["The treatment of older patients with Parkinson\u2019s disease"],"prefix":"10.3238","author":[{"given":"Marija","family":"Djukic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Yoshida-Stiksrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Nau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"key":"10.3238\/arztebl.m2025.0083_ref1","doi-asserted-by":"crossref","unstructured":"Chhetri JK, Mei S, Wang C, Chan P: New horizons in Parkinson\u2018s disease in older populations. Age Ageing 2023; 52: afad186","DOI":"10.1093\/ageing\/afad186"},{"key":"10.3238\/arztebl.m2025.0083_ref2","doi-asserted-by":"crossref","unstructured":"Lingor P, Csoti I, Koschel J, et al.: Der geriatrische Parkinson-Patient \u2013 eine neurologische Herausforderung. Fortschr Neurol Psychiatr 2016; 84 Suppl 1: 41\u20137","DOI":"10.1055\/s-0042-103585"},{"key":"10.3238\/arztebl.m2025.0083_ref3","doi-asserted-by":"crossref","unstructured":"Chang TY, Yang CP, Chen YH, Lin CH, Chang MH: Age-stratified risk of dementia in Parkinson\u2018s disease: A nationwide, population-based, retrospective cohort study in Taiwan. Front Neurol 2021;12: 748096","DOI":"10.3389\/fneur.2021.748096"},{"key":"10.3238\/arztebl.m2025.0083_ref4","doi-asserted-by":"crossref","unstructured":"Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG: The Sydney multicenter study of Parkinson\u2018s disease: The inevitability of dementia at 20 years. Mov Disord 2008; 23: 837\u201344","DOI":"10.1002\/mds.21956"},{"key":"10.3238\/arztebl.m2025.0083_ref5","doi-asserted-by":"crossref","unstructured":"Ffytche DH, Creese B, Politis M, et al.: The psychosis spectrum in Parkinson disease. Nat Rev Neurol 2017; 13: 81\u201395","DOI":"10.1038\/nrneurol.2016.200"},{"key":"10.3238\/arztebl.m2025.0083_ref6","doi-asserted-by":"crossref","unstructured":"Wehling M, Burkhardt H: Arzneitherapie f\u00fcr \u00c4ltere. Heidelberg, Berlin: Springer 2019","DOI":"10.1007\/978-3-662-58905-2"},{"key":"10.3238\/arztebl.m2025.0083_ref7","unstructured":"H\u00f6glinger G, Trenkwalder C, et al.: Parkinson-Krankheit, S2k-Leitlinie, 2023. In: Deutsche Gesellschaft f\u00fcr Neurologie (eds.). Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. www.dgn.org\/leitlinien (last accessed on 27 October 2024)."},{"key":"10.3238\/arztebl.m2025.0083_ref8","doi-asserted-by":"crossref","unstructured":"Nyholm D: Pharmacokinetic optimisation in the treatment of Parkinson\u2018s disease: An update. Clin Pharmacokinet 2006; 45: 109\u201336","DOI":"10.2165\/00003088-200645020-00001"},{"key":"10.3238\/arztebl.m2025.0083_ref9","doi-asserted-by":"crossref","unstructured":"Hardoff R, Sula M, Tamir A, et al.: Gastric emptying time and gastric motility in patients with Parkinson\u2019s disease. Mov Disord 2001; 16: 1041\u20137","DOI":"10.1002\/mds.1203"},{"key":"10.3238\/arztebl.m2025.0083_ref10","doi-asserted-by":"crossref","unstructured":"Leenders KL, Poewe WH, Palmer AJ, et al.: Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography. Ann Neurol 1986; 20: 258\u201362","DOI":"10.1002\/ana.410200212"},{"key":"10.3238\/arztebl.m2025.0083_ref11","doi-asserted-by":"crossref","unstructured":"Nyholm D, Lennernas H, Gomes-Trolin C, et al.: Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson\u2019s disease on individual drug combinations. Clin Neuropharmacol 2002; 25: 89\u201396","DOI":"10.1097\/00002826-200203000-00006"},{"key":"10.3238\/arztebl.m2025.0083_ref12","doi-asserted-by":"crossref","unstructured":"Simon N, Gantcheva R, Bruguerolle B, et al.: The effects of a normal protein diet on levodopa plasma kinetics in advanced Parkinson\u2019s disease. Parkinsonism Relat Disord 2004;10:137\u201342","DOI":"10.1016\/j.parkreldis.2003.10.004"},{"key":"10.3238\/arztebl.m2025.0083_ref13","doi-asserted-by":"crossref","unstructured":"Pfeiffer RF: Antiparkinsonian agents: Drug interactions of clinical significance. Drug Saf 1996; 14: 343\u201354","DOI":"10.2165\/00002018-199614050-00006"},{"key":"10.3238\/arztebl.m2025.0083_ref14","unstructured":"Yeh KC, August TF, Bush DF, et al.: Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989; 39(11 Suppl 2): 25\u201338."},{"key":"10.3238\/arztebl.m2025.0083_ref15","doi-asserted-by":"crossref","unstructured":"LeWitt PA, Hauser RA, Pahwa R, et al.: Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson\u2018s disease: A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019; 18: 145\u201354","DOI":"10.1016\/S1474-4422(18)30405-8"},{"key":"10.3238\/arztebl.m2025.0083_ref16","doi-asserted-by":"crossref","unstructured":"Luinstra M, Rutgers W, van Laar T, et al.: Pharmacokinetics and tolerability of inhaled levodopa from a new dry-powder inhaler in patients with Parkinson\u2018s disease. Ther Adv Chronic Dis 2019; 10: 2040622319857617","DOI":"10.1177\/2040622319857617"},{"key":"10.3238\/arztebl.m2025.0083_ref17","doi-asserted-by":"crossref","unstructured":"Luley MC, Loleit T, Knopf E, Djukic M, Cri\u00e9e CP, Nau R: Training improves the handling of inhaler devices and reduces the severity of symptoms in geriatric patients suffering from chronic-obstructive pulmonary disease. BMC Geriatr 2020; 20: 398","DOI":"10.1186\/s12877-020-01804-4"},{"key":"10.3238\/arztebl.m2025.0083_ref18","doi-asserted-by":"crossref","unstructured":"Kempster PA, Frankel JP, Bovingdon M, et al.: Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson\u2019s disease. J Neural Neurosurg Psychiatry 1989 Jun; 52: 718\u201323","DOI":"10.1136\/jnnp.52.6.718"},{"key":"10.3238\/arztebl.m2025.0083_ref19","doi-asserted-by":"crossref","unstructured":"Contin M, Riva R, Martinelli P, et al.: Levodopa therapy monitoring in patients with Parkinson disease: A kinetic-dynamic approach. Ther Drug Monit 2001; 23: 621\u20139","DOI":"10.1097\/00007691-200112000-00005"},{"key":"10.3238\/arztebl.m2025.0083_ref20","doi-asserted-by":"crossref","unstructured":"Nausieda PA, Pfeiffer RF, Tagliati M, et al.: A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson\u2019s disease. Clin Ther 2005; 27: 58\u201363","DOI":"10.1016\/j.clinthera.2005.01.004"},{"key":"10.3238\/arztebl.m2025.0083_ref21","doi-asserted-by":"crossref","unstructured":"Stocchi F, Fabbri L, Vecsei L, et al.: Clinical efficacy of a single afternoon dose of effervescent levodopa-carbidopa preparation (CHF 1512) in fluctuating Parkinson disease. Clin Neuropharmacol 2007; 30: 18\u201324","DOI":"10.1097\/01.WNF.0000236762.77913.C6"},{"key":"10.3238\/arztebl.m2025.0083_ref22","doi-asserted-by":"crossref","unstructured":"Jansen EN, Meerwaldt JD: Madopar HBS in Parkinson patients with nocturnal akinesia. Clin Neurol Neurosurg 1988; 90: 35\u20139","DOI":"10.1016\/S0303-8467(88)80007-6"},{"key":"10.3238\/arztebl.m2025.0083_ref23","doi-asserted-by":"crossref","unstructured":"Fabbri M, Ferreira JJ, Rascol O: COMT inhibitors in the management of Parkinson\u2018s disease. CNS Drugs 2022; 36: 261\u201382","DOI":"10.1007\/s40263-021-00888-9"},{"key":"10.3238\/arztebl.m2025.0083_ref24","doi-asserted-by":"crossref","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators: Opicapone as an adjunct to levodopa in patients with Parkinson\u2018s disease and end-of-dose motor fluctuations: A randomised, double-blind, controlled trial. Lancet Neurol 2016; 15: 154\u201365","DOI":"10.1016\/S1474-4422(15)00336-1"},{"key":"10.3238\/arztebl.m2025.0083_ref25","doi-asserted-by":"crossref","unstructured":"Jost WH, Buhmann C, Classen J, et al.: Stellenwert der COMT-Hemmer in der Therapie motorischer Fluktuationen. Nervenarzt 2022; 93: 1035\u201345","DOI":"10.1007\/s00115-021-01237-3"},{"key":"10.3238\/arztebl.m2025.0083_ref26","doi-asserted-by":"crossref","unstructured":"Umemoto G, Furuya H: Management of dysphagia in patients with Parkinson\u2018s disease and related disorders. Intern Med 2020; 59: 7\u201314","DOI":"10.2169\/internalmedicine.2373-18"},{"key":"10.3238\/arztebl.m2025.0083_ref27","doi-asserted-by":"crossref","unstructured":"Othman AA, Chatamra K, Mohamed ME, et al.: Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in Japanese subjects with advanced Parkinson\u2018s disease: pharmacokinetics and pilot efficacy and safety. Clin Pharmacokinet 2015; 54: 975\u201384","DOI":"10.1007\/s40262-015-0265-3"},{"key":"10.3238\/arztebl.m2025.0083_ref28","doi-asserted-by":"crossref","unstructured":"Nyholm D, Jost WH: Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson\u2018s disease: Real-world experience and practical guidance. Ther Adv Neurol Disord 2022; 15: 17562864221108018","DOI":"10.1177\/17562864221108018"},{"key":"10.3238\/arztebl.m2025.0083_ref29","doi-asserted-by":"crossref","unstructured":"Soileau MJ, Aldred J, Budur K, et al.: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: A randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 2022; 21: 1099\u2013109","DOI":"10.1016\/S1474-4422(22)00400-8"},{"key":"10.3238\/arztebl.m2025.0083_ref30","doi-asserted-by":"crossref","unstructured":"Weintraub D, Chiang C, Kim HM, et al.: Association of antipsychotic use with mortality risk in patients with Parkinson disease. JAMA Neurol 2016; 73: 535\u201341","DOI":"10.1001\/jamaneurol.2016.0031"},{"key":"10.3238\/arztebl.m2025.0083_ref31","doi-asserted-by":"crossref","unstructured":"Witt K, Levin J, van Eimeren T, Hasan A, Ebersbach G; German Parkinson\u2019s Guideline Group: Diagnostics and treatment of impulse control disorders, psychosis and delirium: Systemic review-based recommendations\u2014guideline \u201eParkinson\u2018s disease\u201c of the German Society of Neurology. J Neurol 2024; 271: 7402\u201321","DOI":"10.1007\/s00415-024-12576-x"},{"key":"10.3238\/arztebl.m2025.0083_ref32","doi-asserted-by":"crossref","unstructured":"Friedman JH, Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson\u2018s disease. N Engl J Med 1999; 340: 757\u201363","DOI":"10.1056\/NEJM199903113401003"},{"key":"10.3238\/arztebl.m2025.0083_ref33","doi-asserted-by":"crossref","unstructured":"French Clozapine Parkinson Study Group: Clozapine in drug-induced psychosis in Parkinson\u2018s disease. Lancet 1999; 353: 2041\u20132","DOI":"10.1016\/S0140-6736(99)00860-0"},{"key":"10.3238\/arztebl.m2025.0083_ref34","doi-asserted-by":"crossref","unstructured":"Pollak P, Tison F, Rascol O, et al.: Clozapine in drug induced psychosis in Parkinson\u2018s disease: A randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75: 689\u201395","DOI":"10.1136\/jnnp.2003.029868"},{"key":"10.3238\/arztebl.m2025.0083_ref35","doi-asserted-by":"crossref","unstructured":"Emre M, Aarsland D, Albanese A, et al.: Rivastigmine for dementia associated with Parkinson\u2018s disease. N Engl J Med 2004; 351: 2509\u201318","DOI":"10.1056\/NEJMoa041470"},{"key":"10.3238\/arztebl.m2025.0083_ref36","doi-asserted-by":"crossref","unstructured":"Truong C, Recto C, Lafont C, et al.: Effect of cholinesterase inhibitors on mortality in patients with dementia: A systematic review of randomized and nonrandomized trials. Neurology 2022: 99: e2313\u201325","DOI":"10.1212\/WNL.0000000000201161"},{"key":"10.3238\/arztebl.m2025.0083_ref37","doi-asserted-by":"crossref","unstructured":"Allen NE, Canning CG, Almeida LRS, et al.: Interventions for preventing falls in Parkinson\u2018s disease. Cochrane Database Syst Rev 2022; 6: CD011574","DOI":"10.1002\/14651858.CD011574.pub2"},{"key":"10.3238\/arztebl.m2025.0083_ref38","doi-asserted-by":"crossref","unstructured":"Henderson EJ, Lord SR, Brodie MA, et al.: Rivastigmine for gait stability in patients with Parkinson\u2018s disease (ReSPonD): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 2016; 15: 249\u201358","DOI":"10.1016\/S1474-4422(15)00389-0"},{"key":"10.3238\/arztebl.m2025.0083_ref39","doi-asserted-by":"crossref","unstructured":"Callegari E, Malhotra B, Bungay PJ, et al.: A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011; 72: 235\u201346","DOI":"10.1111\/j.1365-2125.2011.03961.x"},{"key":"10.3238\/arztebl.m2025.0083_ref40","doi-asserted-by":"crossref","unstructured":"Quarracino C, Otero-Losada M, Capani F, P\u00e9rez-Lloret S: State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson\u2018s disease. Expert Opin Pharmacother 2020; 21: 445\u201357","DOI":"10.1080\/14656566.2020.1713097"},{"key":"10.3238\/arztebl.m2025.0083_ref41","unstructured":"Bauer J, Becker C, Denkinger M, Wirth R: Geriatrie \u2013 Das gesamte Spektrum der Altersmedizin f\u00fcr Klinik und Praxis. Stuttgart: Kohlhammer 2024."},{"key":"10.3238\/arztebl.m2025.0083_ref42","unstructured":"Gesundheitsatlas Deutschland des Wissenschaftlichen Instituts der AOK (WIdO) Morbus Parkinson in Deutschland. 2022. https:\/\/www.gesundheitsatlas-deutschland.de\/erkrankung\/parkinson?activeValueType=praevalence&activeLayerType=state (last accessed on 25 February 2025)."},{"key":"10.3238\/arztebl.m2025.0083_ref43","doi-asserted-by":"crossref","unstructured":"Jellinger KA: Very old onset parkinsonism: A clinical-pathological study. Parkinsonism Relat Disord 2018; 57: 39\u201343","DOI":"10.1016\/j.parkreldis.2018.07.015"},{"key":"10.3238\/arztebl.m2025.0083_ref44","doi-asserted-by":"crossref","unstructured":"Bhagavathula AS, Tesfaye W, Vidyasagar K, Fialova D: Polypharmacy and hyperpolypharmacy in older individuals with parkinson\u2018s disease: A systematic review and meta-analysis. Gerontology 2022; 68: 1081\u201390","DOI":"10.1159\/000521214"},{"key":"10.3238\/arztebl.m2025.0083_ref45","doi-asserted-by":"crossref","unstructured":"Klietz M, Greten S, Wegner F, H\u00f6glinger GU: Safety and tolerability of pharmacotherapies for Parkinson\u2018s disease in geriatric patients. Drugs Aging 2019; 36: 511\u201330","DOI":"10.1007\/s40266-019-00654-z"},{"key":"10.3238\/arztebl.m2025.0083_ref46","doi-asserted-by":"crossref","unstructured":"Hauser RA, Espay AJ, Ellenbogen AL, et al.: IPX203 vs immediate-release carbidopa-levodopa for the treatment of motor fluctuations in Parkinson disease: The RISE-PD randomized clinical trial. JAMA Neurol 2023; 80: 1062\u201369","DOI":"10.1001\/jamaneurol.2023.2679"},{"key":"10.3238\/arztebl.m2025.0083_ref47","doi-asserted-by":"crossref","unstructured":"Margolesky J, Singer C: Extended-release oral capsule of carbidopa-levodopa in Parkinson disease. Ther Adv Neurol Disord 2017; 11: 1756285617737728","DOI":"10.1177\/1756285617737728"},{"key":"10.3238\/arztebl.m2025.0083_ref48","doi-asserted-by":"crossref","unstructured":"Poewe W: Catechol-O-methyltransferase inhibition with entacapone: Evidence from controlled clinical trials in Parkinson\u2018s disease. Eur J Neurol 2023;30 Suppl 2: 9\u201314","DOI":"10.1111\/ene.15993"},{"key":"10.3238\/arztebl.m2025.0083_ref49","doi-asserted-by":"crossref","unstructured":"Rocha F, Almeida L, Falc\u00e3o A, et al.: Opicapone: A short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 2013; 76: 763\u201375","DOI":"10.1111\/bcp.12081"},{"key":"10.3238\/arztebl.m2025.0083_ref50","unstructured":"Th\u00fcrmann P, Mann N-K. PRISCUS 2.0-Liste f\u00fcr Deutschland. www.priscus2-0.de\/fileadmin\/media\/PRISCUS_2\/PRISCUS%202_Liste_Anhang_in_DE_nicht_verfuegbare.pdf (last accessed on 26 February 2025)."},{"key":"10.3238\/arztebl.m2025.0083_ref51","doi-asserted-by":"crossref","unstructured":"Gray R, Patel S, Ives N, et al.: Long-term effectiveness of adjuvant treatment with catechol-O-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists among patients with parkinson disease uncontrolled by levodopa therapy: The PD MED randomized clinical trial. JAMA Neurol 2022; 79: 131\u201340","DOI":"10.1001\/jamaneurol.2021.4736"},{"key":"10.3238\/arztebl.m2025.0083_ref52","doi-asserted-by":"crossref","unstructured":"Jost WH: A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2018s disease. J Neural Transm (Vienna) 2022; 129: 723\u201336","DOI":"10.1007\/s00702-022-02465-w"},{"key":"10.3238\/arztebl.m2025.0083_ref53","doi-asserted-by":"crossref","unstructured":"Nomoto M, Iwaki H, Kondo H, Sakurai M: Efficacy and safety of rotigotine in elderly patients with Parkinson\u2018s disease in comparison with the non-elderly: A post hoc analysis of randomized, double-blind, placebo-controlled trials. J Neurol 2018; 265: 253\u201365","DOI":"10.1007\/s00415-017-8671-0"},{"key":"10.3238\/arztebl.m2025.0083_ref54","doi-asserted-by":"crossref","unstructured":"Ibrahim H, Woodward Z, Pooley J, Richfield EW: Rotigotine patch prescription in inpatients with Parkinson\u2018s disease: Evaluating prescription accuracy, delirium and end-of-life use. Age Ageing 2021; 50: 1397\u2013401","DOI":"10.1093\/ageing\/afaa256"},{"key":"10.3238\/arztebl.m2025.0083_ref55","doi-asserted-by":"crossref","unstructured":"Hewer C, Richfield E, Halton C, Alty J: Transdermal rotigotine at end-of-life for Parkinson\u2018s disease: Association with measures of distress. J Pain Symptom Manage 2024; 67: e121\u2013e128","DOI":"10.1016\/j.jpainsymman.2023.10.002"},{"key":"10.3238\/arztebl.m2025.0083_ref56","doi-asserted-by":"crossref","unstructured":"Oertel W, LeWitt P, Giladi N, Ghys L, Grieger F, Boroojerdi B: Treatment of patients with early and advanced Parkinson\u2018s disease with rotigotine transdermal system: Age-relationship to safety and tolerability. Parkinsonism Relat Disord 2013; 19: 37\u201342","DOI":"10.1016\/j.parkreldis.2012.06.009"},{"key":"10.3238\/arztebl.m2025.0083_ref57","doi-asserted-by":"crossref","unstructured":"Siddiqi SH, Abraham NK, Geiger CL, et al.: The human experience with intravenous levodopa. Front Pharmacol 2016; 6: 307","DOI":"10.3389\/fphar.2015.00307"},{"key":"10.3238\/arztebl.m2025.0083_ref58","doi-asserted-by":"crossref","unstructured":"Senek M, Nielsen EI, Nyholm D: Levodopa-entacapone-carbidopa intestinal gel in Parkinson\u2019s disease: A randomized crossover study. Mov Disord 2017; 32: 283\u20136","DOI":"10.1002\/mds.26855"},{"key":"10.3238\/arztebl.m2025.0083_ref59","doi-asserted-by":"crossref","unstructured":"Carbone F, Djamshidian A, Seppi K, Poewe W: Apomorphine for Parkinson\u2018s disease: Efficacy and safety of current and new formulations. CNS Drugs 2019; 33: 905\u201318","DOI":"10.1007\/s40263-019-00661-z"},{"key":"10.3238\/arztebl.m2025.0083_ref60","doi-asserted-by":"crossref","unstructured":"Schr\u00f6ter N, Sajonz BEA, Jost WH, et al.: Advanced therapies in Parkinson\u2018s disease: An individualized approach to their indication. J Neural Transm (Vienna) 2024; 131: 1285\u201393","DOI":"10.1007\/s00702-024-02773-3"},{"key":"10.3238\/arztebl.m2025.0083_ref61","doi-asserted-by":"crossref","unstructured":"Auffret M, Weiss D, Stocchi F, V\u00e9rin M, Jost WH: Access to device-aided therapies in advanced Parkinson\u2018s disease: Navigating clinician biases, patient preference, and prognostic uncertainty. J Neural Transm (Vienna) 2023; 130: 1411\u201332","DOI":"10.1007\/s00702-023-02668-9"},{"key":"10.3238\/arztebl.m2025.0083_ref62","doi-asserted-by":"crossref","unstructured":"Razmkon A, Abdollahifard S, Rezaei H, et al.: Effect of deep brain stimulation on Parkinson disease dementia: A systematic review and meta-analysis. Basic Clin Neurosci 2024; 15: 157\u201364","DOI":"10.32598\/bcn.2021.3420.1"},{"key":"10.3238\/arztebl.m2025.0083_ref63","doi-asserted-by":"crossref","unstructured":"Bouwyn JP, Derrey S, Lefaucheur R, et al.: Age limits for deep brain stimulation of subthalamic nuclei in Parkinson\u2018s disease. J Parkinsons Dis 2016; 6: 393\u2013400","DOI":"10.3233\/JPD-150742"},{"key":"10.3238\/arztebl.m2025.0083_ref64","doi-asserted-by":"crossref","unstructured":"Friedman JH: Movement disorders induced by psychiatric drugs that do not block dopamine receptors. Parkinsonism Relat Disord 2020; 79: 60\u20134","DOI":"10.1016\/j.parkreldis.2020.08.031"},{"key":"10.3238\/arztebl.m2025.0083_ref65","doi-asserted-by":"crossref","unstructured":"Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G: Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson\u2019s disease. Mov Disord 2005; 20: 958\u201363","DOI":"10.1002\/mds.20474"},{"key":"10.3238\/arztebl.m2025.0083_ref66","doi-asserted-by":"crossref","unstructured":"Shotbolt P, Samuel M, Fox C, David AS: A randomized controlled trial of quetiapine for psychosis in Parkinson\u2019s disease. Neuropsychiatr Dis Treat 2009; 5: 327\u201332","DOI":"10.2147\/NDT.S5335"},{"key":"10.3238\/arztebl.m2025.0083_ref67","doi-asserted-by":"crossref","unstructured":"Loeffler MA, Mengel A, Single C, et al.: Subcutaneous foslevodopa in akinetic crisis. A case report from the neurological intensive care unit. Front Med (Lausanne) 2024; 11: 1446345","DOI":"10.3389\/fmed.2024.1446345"},{"key":"10.3238\/arztebl.m2025.0083_ref68","doi-asserted-by":"crossref","unstructured":"Hayden FG, Minocha A, Spyker DA, Hoffman HE: Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother 1985; 28: 216\u201321","DOI":"10.1128\/AAC.28.2.216"},{"key":"10.3238\/arztebl.m2025.0083_ref69","doi-asserted-by":"crossref","unstructured":"Moreau C, Delval A, Tiffreau V, et al.: Memantine for axial signs in Parkinson\u2018s disease: A randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry 2013; 84: 552\u20135","DOI":"10.1136\/jnnp-2012-303182"},{"key":"10.3238\/arztebl.m2025.0083_ref70","doi-asserted-by":"crossref","unstructured":"Wesnes KA, Aarsland D, Ballard C, Londos E: Memantine improves attention and episodic memory in Parkinson\u2018s disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry 2015; 30: 46\u201354","DOI":"10.1002\/gps.4109"},{"key":"10.3238\/arztebl.m2025.0083_ref71","doi-asserted-by":"crossref","unstructured":"Jost WH: Urological problems in Parkinson\u2018s disease: Clinical aspects. J Neural Transm (Vienna) 2013; 120: 587\u201391","DOI":"10.1007\/s00702-012-0914-8"},{"key":"10.3238\/arztebl.m2025.0083_ref72","doi-asserted-by":"crossref","unstructured":"Paschen S, Hansen C, Welzel J, et al.: Effect of lower limb vs. abdominal compression on mobility in orthostatic hypotension: A single-blinded, randomized, controlled, cross-over pilot study in Parkinson\u2018s disease. J Parkinsons Dis 2022; 12: 2531\u201341","DOI":"10.3233\/JPD-223406"},{"key":"10.3238\/arztebl.m2025.0083_ref73","doi-asserted-by":"crossref","unstructured":"Fanciulli A, Leys F, Falup-Pecurariu C, Thijs R, Wenning GK: Management of orthostatic hypotension in Parkinson\u2018s disease. J Parkinsons Dis 2020;10(s1): S57-64","DOI":"10.3233\/JPD-202036"},{"key":"10.3238\/arztebl.m2025.0083_ref74","doi-asserted-by":"crossref","unstructured":"Latt MD, Lewis S, Zekry O, Fung VSC: Factors to consider in the selection of dopamine agonists for older persons with Parkinson\u2018s disease. Drugs Aging 2019; 36:189\u2013202","DOI":"10.1007\/s40266-018-0629-0"},{"key":"10.3238\/arztebl.m2025.0083_ref75","doi-asserted-by":"crossref","unstructured":"Simeonova M, de Vries F, Pouwels S, et al.: Increased risk of all-cause mortality associated with domperidone use in Parkinson\u2018s patients: A population-based cohort study in the UK. Br J Clin Pharmacol 2018; 84: 2551\u201361","DOI":"10.1111\/bcp.13708"},{"key":"10.3238\/arztebl.m2025.0083_ref76","doi-asserted-by":"crossref","unstructured":"Pathak A, Senard JM: Pharmacology of orthostatic hypotension in Parkinson\u2018s disease: From pathophysiology to management. Expert Rev Cardiovasc Ther 2004; 2: 393\u2013403","DOI":"10.1586\/14779072.2.3.393"},{"key":"10.3238\/arztebl.m2025.0083_ref77","doi-asserted-by":"crossref","unstructured":"Miller E, Wiener L, Bloomfield D: Etilefrine in the treatment of levodopa-induced orthostatic hypotension. Arch Neurol 1973; 29: 99\u2013103","DOI":"10.1001\/archneur.1973.00490260043008"},{"key":"10.3238\/arztebl.m2025.0083_ref78","doi-asserted-by":"crossref","unstructured":"Kaufmann H, Freeman R, Biaggioni I, et al.: Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial. Neurology 2014; 83: 328\u201335","DOI":"10.1212\/WNL.0000000000000615"},{"key":"10.3238\/arztebl.m2025.0083_ref79","doi-asserted-by":"crossref","unstructured":"Hommel ALAJ, Meinders MJ, Weerkamp NJ, et al.: Optimizing treatment in undertreated late-stage Parkinsonism: A pragmatic randomized trial. J Parkinsons Dis 2020; 10: 1171\u201384","DOI":"10.3233\/JPD-202033"},{"key":"10.3238\/arztebl.m2025.0083_ref80","doi-asserted-by":"crossref","unstructured":"Robertson DR, Wood ND, Everest H, et al.: The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 1989; 28: 61\u20139","DOI":"10.1111\/j.1365-2125.1989.tb03506.x"},{"key":"10.3238\/arztebl.m2025.0083_ref81","doi-asserted-by":"crossref","unstructured":"M\u00fcller T, Woitalla D, Saft C, et al.: Levodopa in plasma correlates with body weight of Parkinsonian patients. Parkinsonism Relat Disord 2000; 6: 171\u20133.","DOI":"10.1016\/S1353-8020(00)00005-5"},{"key":"10.3238\/arztebl.m2025.0083_ref82","doi-asserted-by":"crossref","unstructured":"Martinelli P, Contin M, Scaglione C, et al.: Levodopa pharmacokinetics and dyskinesias: Are there sex-related differences? Neurol Sci 2003; 24: 192\u20133.","DOI":"10.1007\/s10072-003-0125-z"},{"key":"10.3238\/arztebl.m2025.0083_ref83","doi-asserted-by":"crossref","unstructured":"Tariot PN, Cummings JL, Soto-Martin ME, et al.: Trial of pimavanserin in dementia-related psychosis. N Engl J Med 2021; 385: 309\u201319.","DOI":"10.1056\/NEJMoa2034634"},{"key":"10.3238\/arztebl.m2025.0083_ref84","doi-asserted-by":"crossref","unstructured":"Fernandez HH, Standaert DG, Hauser RA, et al.: Levodopa-carbidopa intestinal gel in advanced Parkinson\u2018s disease: Final 12-month, open-label results. Mov Disord 2014; 30: 500\u20139.","DOI":"10.1002\/mds.26123"},{"key":"10.3238\/arztebl.m2025.0083_ref85","doi-asserted-by":"crossref","unstructured":"Ebersbach G, Ebersbach A, Edler D, et al.: Comparing exercise in Parkinson\u2018s disease\u2014the Berlin LSVT\u00aeBIG study. Mov Disord 2010; 25: 1902\u20138.","DOI":"10.1002\/mds.23212"},{"key":"10.3238\/arztebl.m2025.0083_ref86","doi-asserted-by":"crossref","unstructured":"Tomlinson CL, Patel S, Meek C, et al.: Physiotherapy versus placebo or no intervention in Parkinson\u2018s disease. Cochrane Database Syst Rev 2013; 2013: CD002817.","DOI":"10.1002\/14651858.CD002817.pub4"},{"key":"10.3238\/arztebl.m2025.0083_ref87","doi-asserted-by":"crossref","unstructured":"Hortob\u00e1gyi T, Sipos D, Borb\u00e9ly G, et al.: Detraining slows and maintenance training over 6 years halts Parkinsonian symptoms-progression. Front Neurol 2021; 12: 737726.","DOI":"10.3389\/fneur.2021.737726"},{"key":"10.3238\/arztebl.m2025.0083_ref88","doi-asserted-by":"crossref","unstructured":"Ferraz DD, Trippo KV, Duarte GP, et al.: The effects of functional training, bicycle exercise, and exergaming on walking capacity of elderly patients with Parkinson disease: A pilot randomized controlled single-blinded trial. Arch Phys Med Rehabil 2018; 99: 826\u201333.","DOI":"10.1016\/j.apmr.2017.12.014"},{"key":"10.3238\/arztebl.m2025.0083_ref89","unstructured":"Keus SHJ, Munneke M, Graziano M, et al.: European Physiotherapy Guideline for Parkinson\u2019s disease. 2014. KNGF\/ParkinsonNet, Netherlands. www.parkinsonnet.nl\/app\/uploads\/sites\/3\/2019\/11\/Parkinson_Leitlinie_Physiotherapeuten_2015.pdf (last accessed on 17 November 2024)."},{"key":"10.3238\/arztebl.m2025.0083_ref90","doi-asserted-by":"crossref","unstructured":"Nascimento CM, Ayan C, Cancela JM, Gobbi LT, Gobbi S, Stella F: Effect of a multimodal exercise program on sleep disturbances and instrumental activities of daily living performance on Parkinson\u2018s and Alzheimer\u2018s disease patients. Geriatr Gerontol Int 2014; 14: 259\u201366.","DOI":"10.1111\/ggi.12082"},{"key":"10.3238\/arztebl.m2025.0083_ref91","doi-asserted-by":"crossref","unstructured":"Ashburn A, Pickering R, McIntosh E, et al.: Exercise- and strategy-based physiotherapy-delivered intervention for preventing repeat falls in people with Parkinson\u2018s: The PDSAFE RCT. Health Technol Assess 2019; 23: 1\u2013150.","DOI":"10.3310\/hta23360"},{"key":"10.3238\/arztebl.m2025.0083_ref92","doi-asserted-by":"crossref","unstructured":"Chivers Seymour K, Pickering R, Rochester L, et al.: Multicentre, randomised controlled trial of PDSAFE, a physiotherapist-delivered fall prevention programme for people with Parkinson\u2018s. J Neurol Neurosurg Psychiatry. 2019; 90: 774\u201382.","DOI":"10.1136\/jnnp-2018-319448"},{"key":"10.3238\/arztebl.m2025.0083_ref93","doi-asserted-by":"crossref","unstructured":"Ge Y, Zhao W, Zhang L, et al.: Home physical therapy versus telerehabilitation in improving motor function and quality of life in Parkinson\u2018s disease: A randomized controlled trial. BMC Geriatr 2024; 24: 968.","DOI":"10.1186\/s12877-024-05529-6"},{"key":"10.3238\/arztebl.m2025.0083_ref94","doi-asserted-by":"crossref","unstructured":"Ćwiękała-Lewis KJ, Gallek M, Taylor-Piliae RE: The effects of Tai Chi on physical function and well-being among persons with Parkinson\u2018s disease: A systematic review. J Bodyw Mov Ther 2017; 21: 414\u201321.","DOI":"10.1016\/j.jbmt.2016.06.007"},{"key":"10.3238\/arztebl.m2025.0083_ref95","doi-asserted-by":"crossref","unstructured":"Kwon SH, Park JK, Koh YH: A systematic review and meta-analysis on the effect of virtual reality-based rehabilitation for people with Parkinson\u2018s disease. J Neuroeng Rehabil 2023; 20: 94.","DOI":"10.1186\/s12984-023-01219-3"},{"key":"10.3238\/arztebl.m2025.0083_ref96","doi-asserted-by":"crossref","unstructured":"Marazzi S, Kiper P, Palmer K, Agostini M, Turolla A: Effects of vibratory stimulation on balance and gait in Parkinson\u2018s disease: A systematic review and meta-analysis. Eur J Phys Rehabil Med 2021; 57: 254\u201364.","DOI":"10.23736\/S1973-9087.20.06099-2"},{"key":"10.3238\/arztebl.m2025.0083_ref97","doi-asserted-by":"crossref","unstructured":"Ernst M, Folkerts AK, Gollan R, et al.: Physical exercise for people with Parkinson\u2018s disease: A systematic review and network meta-analysis. Cochrane Database Syst Rev 2024; 4: CD013856.","DOI":"10.1002\/14651858.CD013856.pub3"},{"key":"10.3238\/arztebl.m2025.0083_ref98","doi-asserted-by":"crossref","unstructured":"Wood J, Henderson W, Foster ER: Occupational therapy practice guidelines for people with Parkinson\u2018s disease. Am J Occup Ther 2022; 76: 7603397010.","DOI":"10.5014\/ajot.2022.763001"},{"key":"10.3238\/arztebl.m2025.0083_ref99","doi-asserted-by":"crossref","unstructured":"Herd CP, Tomlinson CL, Deane KH, et al.: Speech and language therapy versus placebo or no intervention for speech problems in Parkinson\u2018s disease. Cochrane Database Syst Rev 2012; 2012: CD002812.","DOI":"10.1002\/14651858.CD002812.pub2"},{"key":"10.3238\/arztebl.m2025.0083_ref100","doi-asserted-by":"crossref","unstructured":"Schindler A, Pizzorni N, Cereda E, et al.: Consensus on the treatment of dysphagia in Parkinson\u2018s disease. J Neurol Sci 2021; 430: 120008.","DOI":"10.1016\/j.jns.2021.120008"},{"key":"10.3238\/arztebl.m2025.0083_ref101","doi-asserted-by":"crossref","unstructured":"Machado Sotomayor MJ, Arufe-Gir\u00e1ldez V, Ru\u00edz-Rico G, Navarro-Pat\u00f3n R: Music therapy and Parkinson\u2018s disease: A systematic review from 2015\u20132020. Int J Environ Res Public Health 2021; 18: 11618.","DOI":"10.3390\/ijerph182111618"},{"key":"10.3238\/arztebl.m2025.0083_ref102","doi-asserted-by":"crossref","unstructured":"Orgeta V, McDonald KR, Poliakoff E, Hindle JV, Clare L, Leroi I: Cognitive training interventions for dementia and mild cognitive impairment in Parkinson\u2018s disease. Cochrane Database Syst Rev 2020; 2: CD011961.","DOI":"10.1002\/14651858.CD011961.pub2"},{"key":"10.3238\/arztebl.m2025.0083_ref103","doi-asserted-by":"crossref","unstructured":"Gavelin HM, Domell\u00f6f ME, Leung I, et al.: Computerized cognitive training in Parkinson\u2018s disease: A systematic review and meta-analysis. Ageing Res Rev 2022; 80: 101671.","DOI":"10.1016\/j.arr.2022.101671"},{"key":"10.3238\/arztebl.m2025.0083_ref104","doi-asserted-by":"crossref","unstructured":"Vaughan CP, Burgio KL, Goode PS, et al.: Behavioral therapy for urinary symptoms in Parkinson\u2018s disease: A randomized clinical trial. Neurourol Urodyn 2019; 38: 1737\u201344.","DOI":"10.1002\/nau.24052"},{"key":"10.3238\/arztebl.m2025.0083_ref105","doi-asserted-by":"crossref","unstructured":"Li J, Mi TM, Zhu BF, et al.: High-frequency repetitive transcranial magnetic stimulation over the primary motor cortex relieves musculoskeletal pain in patients with Parkinson\u2018s disease: A randomized controlled trial. Parkinsonism Relat Disord 2020; 80: 113\u20139.","DOI":"10.1016\/j.parkreldis.2020.07.006"},{"key":"10.3238\/arztebl.m2025.0083_ref106","doi-asserted-by":"crossref","unstructured":"Mi TM, Garg S, Ba F, et al.: High-frequency rTMS over the supplementary motor area improves freezing of gait in Parkinson\u2018s disease: A randomized controlled trial. Parkinsonism Relat Disord 2019; 68: 85\u201390.","DOI":"10.1016\/j.parkreldis.2019.10.009"},{"key":"10.3238\/arztebl.m2025.0083_ref107","doi-asserted-by":"crossref","unstructured":"Lin F, Su Y, Weng Y, et al.: The effects of bright light therapy on depression and sleep disturbances in patients with Parkinson\u2018s disease: A systematic review and meta-analysis of randomized controlled trials. Sleep Med 2021; 83: 280\u20139.","DOI":"10.1016\/j.sleep.2021.03.035"},{"key":"10.3238\/arztebl.m2025.0083_ref108","doi-asserted-by":"crossref","unstructured":"Connor KI, Cheng EM, Barry F, et al.: Randomized trial of care management to improve Parkinson disease care quality. Neurology 2019; 92: e1831\u201342.","DOI":"10.1212\/WNL.0000000000007324"},{"key":"10.3238\/arztebl.m2025.0083_ref109","doi-asserted-by":"crossref","unstructured":"Ziegler K, Fietzek UM, Ceballos-Baumann AO: Multimodale Therapieangebote bei der Parkinson-Krankheit. Nervenheilkunde 2025; 44: 86\u201397.","DOI":"10.1055\/a-2449-1461"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T10:54:33Z","timestamp":1752836073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":109,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0083","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]}}}